Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 2511 to 2520 of 2582 total matches.
Rabies Vaccine
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990 (Issue 834)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Human rabies continues to be rare in the USA, but animal rabies is becoming more common. An animal epizootic in the mid-Atlantic states, involving especially raccoons, has recently spread into the northeastern states.
Laser Coronary Angioplasty
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991 (Issue 836)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Percutaneous transluminal coronary angioplasty (PTCA), in which a balloon catheter distends the vessel at the site of obstruction (Medical Letter, 25:97, 1983), is now an established therapeutic option for treatment of patients with coronary artery disease, especially those with single-vessel disease. Major problems related to PTCA include acute occlusion during the procedure (usually caused by dissection), restenosis at the site of angioplasty, and inability to treat complete occlusions and long or ostial lesions. Some cardiologists have tried using lasers during PTCA to deal with these...
Zinc for the Common Cold
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997 (Issue 993)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Results of a recent study suggested that zinc gluconate may be effective in treating the common cold (SB Mossad et al, Ann Intern Med, 125:81, July 15, 1996). Zinc gluconate lozenges, sometimes combined with vitamin C or other ingredients, are available in pharmacies and health food stores throughout the USA.
Sucralose--A New Artificial Sweetener
The Medical Letter on Drugs and Therapeutics • Jul 03, 1998 (Issue 1030)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Sucralose (Splenda - McNeil Specialty) has been approved by the FDA for use as a nonnutritive sweetener in beverages, baked goods and other foods, and as a tabletop sugar substitute (Fed Reg, 63:16417, April 3, 1998). Other non-caloric sweeteners available in the USA include saccharin (Sweet'n Low, and others), aspartame (NutraSweet, Equal) and acesulfame potassium (Sunette - Medical Letter, 30:116, 1988).
The Atkins Diet
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000 (Issue 1080)
The Medical Letter
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 Main ...
Nearly 30 years after the first publication of Dr. Atkins' Diet Revolution promoting a high-protein, extremely low-carbohydrate diet, patients once again are asking their physicians about the Atkins diet.
Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010 (Issue 1344)
The Medical Letter®
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
The antibiotic aztreonam is now available as an inhalation solution (Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa. It is the second inhaled antibiotic to be FDA-approved for this indication in CF patients; the aminoglycoside tobramycin (Tobi) was the first. Inhaled antibiotics offer the advantage of high airway concentrations while minimizing systemic side effects.
A New Scorpion Antivenom
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1393)
June 25, 2012 ...
Anascorp (Rare Disease Therapeutics), an intravenously
administered antivenom derived from horse
serum, has been approved by the FDA for treatment of
clinical signs of scorpion envenomation.
Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jul 23, 2012 (Issue 1395)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1395)
July 23, 2012 ...
Pertuzumab (Perjeta – Roche/Genentech), a humanized
monoclonal antibody, has been approved by the FDA for
use in combination with trastuzumab (Herceptin) and
docetaxel (Taxotere, and others) for first-line treatment of
human epidermal growth factor receptor 2 (HER2)-positive
metastatic breast cancer.
Nutritional Supplements for Age-Related Macular Degeneration Revisited
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013 (Issue 1419)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1419)
June 24, 2013
Published ...
The results of the Age-Related Eye Disease Study 2
(AREDS2) have now been published. The primary purpose
of the study was to evaluate the efficacy and safety
of the carotenoids lutein and zeaxanthin and the
omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA)
in reducing the risk of developing advanced age-related
macular degeneration (AMD). A secondary goal was to
test the effects of reducing the amount of zinc and eliminating
beta carotene from the original AREDS formulation.
Beta carotene has been shown to increase the
risk of...
Belotero Balance for Wrinkles and Folds
The Medical Letter on Drugs and Therapeutics • Oct 28, 2013 (Issue 1428)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1428)
October 28, 2013
Published ...
Belotero Balance (Merz), an injectable hyaluronic acid
dermal filler, has been approved by the FDA for temporary
correction of moderate-to-severe facial wrinkles
and folds. Several other hyaluronic acid products are
also available for this indication (e.g., Restylane,
Perlane, Juvéderm). They have supplanted bovine collagen
products, which persist for a shorter time and
cause more allergic reactions.